19 results about "Acacetin" patented technology

The invention belongs to the technical field of disease prevention and treatment and aquaculture, and relates to application of acacetin in preparation of a medicine for preventing and treating white spot syndrome. The invention discloses that the acacetin has the biological activity of resisting the white spot syndrome virus for the first time, verifies that the acacetin can obviously inhibit the replication of the white spot syndrome virus in the procambarus clarkia body, and simultaneously improves the survival rate of the procambarus clarkia infected by the white spot syndrome virus. The acacetin has a good antiviral effect on the white spot syndrome virus in crustacean aquaculture, and can be applied to prevention and treatment of aquatic animal diseases caused by the white spot syndrome virus.

The invention discloses an acacetin and isonicotinamide eutectic, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and isonicotinamide, and the molecular formula of the eutectic substance is (C16H12O5). (C6H6N2O), the invention relates to a preparation method of a cocrystal of acacetin and isonicotinamide. The acacetin and isonicotinamide eutectic is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.

The invention discloses a specific small-molecule inhibitor aiming at a transcription factor Creb1 and application of the specific small-molecule inhibitor, Acacetin can be combined with a 38th glutamine (Q) residue and a 68th glycine (G) residue of the Creb1 to inhibit the phosphorylation level of the Creb1, so that the transcriptional activity of the Creb1 is weakened. The invention provides an application of Acacetin or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing and / or treating diseases related to abnormal activation of Creb1, wherein the diseases include but are not limited to tumors, inflammatory diseases, metabolic diseases, nervous system diseases and fibrosis diseases.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.

The invention relates to a preparation method of high-purity acacetin-7-O-glucuronide, which comprises the following steps of: crushing dry branches and leaves of a verbenaceae plant millettian tree, performing reflux extraction by using a 60-80% methanol solution, combining extracting solutions, and concentrating to obtain an extract; carrying out gel column chromatography on the extract, carrying out gradient elution by using a methanol-water system, detecting by using thin-layer chromatography (TLC), collecting eluent containing acacetin-7-O-glucuronide, merging, and concentrating under reduced pressure to obtain crude fraction of acacetin-7-O-glucuronide. And separating and purifying by using preparative high performance liquid chromatography (PHPLC), and detecting each part of collected eluent by using high performance liquid chromatography (HPLC) to obtain the acacetin-7-O-glucuronide component with the purity of more than 98%. And carrying out TLC and HPLC purity detection and content determination on the obtained product, and establishing a quality control method. The process is simple and reasonable in design, high in separation speed, short in production period, high in product purity, controllable in quality and suitable for industrial production.

The invention belongs to the technical field of medicines, and discloses acacetin as shown in a formula (I) and application of pharmacodynamically acceptable salts thereof in preparation of drugs for preventing, relieving and / or treating autoimmune demyelination diseases. On a mouse experimental autoimmune encephalomyelitis model, acacetin shows a good treatment effect, and can effectively prevent and treat pathological changes and disease progression, relieve disease severity and inhibit LPS-stimulated microglial BV2 cells from releasing an inflammatory mediator, thereby providing a new drug and a new structure for clinical treatment.

The application discloses a method for screening sEH inhibitors from traditional Chinese medicine components and application, and comprises the following steps: constructing a pharmacophore model composed of 5 pharmacodynamic characteristic elements, i.e., 1 aromatic ring center, 2 hydrophobic centers and 2 hydrogen bond donors, to virtually screen traditional Chinese medicine components, and then performing molecular docking screening and in-vitro sEH activity inhibition experiments, so that isorhamnetin, acacetin, hydroxysafflor yellow A, cirsiline or cosmosiin are screened for the first time and have sEH inhibition effects, and the IC 50 range is 13.63 μM-37.81 μM, K i value range is 7.612 μM-28.05 μM, and the sEH inhibitors can be applied to preparation.

The invention discloses an acacetin and zolpidem eutectic crystal, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and zolpidem, and the molecular formula of the eutectic substance is (C16H12O5). (C19H21N3O), the invention relates to a preparation method of a cocrystal of acacetin and zolpidem. The acacetin and zolpidem eutectic crystal is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to acacetin-containing lipid nanoparticles for a pulmonary inhalation type mRNA vaccine as well as a preparation method and application of the acacetin-containing lipid nanoparticles. The lipid nano-particle takes acacetin as a functional fifth component, is jointly composed of ionized lipid, neutral auxiliary lipid, cholesterol and polyethylene glycol lipid, and can effectively wrap mRNA (messenger Ribonucleic Acid) of an encoding antigen. According to the preparation method, high-efficiency compounding of lipid and mRNA is realized through a microfluidic technology, the particle size of the obtained particles is adaptive to lung targeting, alveolar macrophage removal can be reduced, mRNA is protected from peroxidation damage, and vaccine response is enhanced through the immunomodulatory effect of acacetin. The system can be prepared into a lung inhalation type mRNA vaccine, is used for preventing and controlling respiratory tract infectious diseases, has high-efficiency delivery, strong immunization and good safety, and provides a new scheme for construction of a lung immune barrier.

The application belongs to the technical field of disease prevention and treatment and aquaculture, and relates to application of acacetin in preparation of a drug for preventing and treating white spot syndrome. The application discloses for the first time that acacetin has the biological activity of resisting white spot syndrome virus, verifies that the acacetin can significantly inhibit the replication of the white spot syndrome virus in the body of a procambarus clarkii, and simultaneously improve the survival rate of the procambarus clarkii infected by the white spot syndrome virus. The acacetin has good antiviral effect on the white spot syndrome virus in crustacean aquaculture, and can be applied to prevention and treatment of water animal diseases caused by the white spot syndrome virus.

The invention discloses an application of acacetin in preparation of a medicine for treating asthenospermia, and acacetin and beta-nicotinamide mononucleotide NMN (EVs (at) N + A for short are jointly delivered through a platform based on engineered extracellular vesicles. According to the invention, a stable and traceable nano platform is provided for male infertility treatment, and the concept of AIE-pharmacology is determined as a potential reform diagnosis and treatment strategy.

In the present application, an agent for enhancing saltiness and / or umami of an oral ingestion product containing a component imparting saltiness and / or a component imparting umami, the agent containing one or two or more flavonoid components selected from naringenin, luteolin, pinocembrin, liquiritigenin, apigenin, and acacetin, or salts thereof, as an active ingredient, and the like are disclosed as embodiments thereof.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a UHPLC-QE-MS method for separating and determining fingerprint components in a traditional Chinese medicine composition. The traditional Chinese medicine composition consists of the following components in parts by mass: 1-5 parts of leech and 0.5-2.5 parts of ligusticum wallichii. The fingerprint component is prepared from any one or more of saikoside D3, jatrorrhizine, palmatine, (+)-zearalene, oroxylin A, epiberberine, acacetin, genistein, timosaponin B II and tangeretin. According to the method, octadecyl silane bonded silica gel is used as a chromatographic column filler, a 0.05-0.5% formic acid aqueous solution is used as a mobile phase A, a 0.05-0.5% formic acid acetonitrile solution is used as a mobile phase B, fingerprint components in the traditional Chinese medicine composition are separated through linear elution gradient, and mass spectrometry is adopted for detection. Based on the method, the quality consistency and stability of the preparation can be effectively monitored, and support is provided for quality control of the preparation.

The invention relates to application of acacetin in alcoholic hepatitis, and relates to the technical field of medicines. According to the application of the acacetin in the alcoholic hepatitis, the acacetin can effectively reduce fatty acid synthase expression, relieve stem cell vacuolar degeneration and reduce cell apoptosis, so that the alcoholic hepatitis is relieved and treated, and the acacetin has an excellent application prospect in the aspect of development of drugs for treating the alcoholic hepatitis.

The application discloses a combined medicine of acacetin acetate and a CDK4 / 6 inhibitor, and relates to the technical field of medicines. The medicine composition comprises a CDK6 negative regulator and a CDK4 / 6 inhibitor; the CDK6 negative regulator comprises acacetin acetate or a baicalein derivative. The application proposes a treatment scheme of the combined medicine of acacetin acetate and the CDK4 / 6 inhibitor or a treatment scheme of the combined medicine of the baicalein derivative and the CDK4 / 6 inhibitor, which exhibits excellent synergistic effect and can effectively improve the treatment effect on patients who are not sensitive to the CDK4 / 6 inhibitor.

The invention discloses an eutectic of acacetin and 4, 4 '-dipyridyl, the molar ratio of the acacetin to the 4, 4'-dipyridyl is 2: 1, and compared with the acacetin, the eutectic has higher solubility, dissolution rate, bioavailability and activity.

The invention discloses a cocrystal of acacetin and 2, 2 '-dipyridyl, the molar ratio of the acacetin to the 2, 2'-dipyridyl is 2: 1, and the cocrystal has higher solubility, dissolution rate and bioavailability compared with the acacetin.

The application discloses a propolis extract and a production process thereof. According to mass percentage, the propolis extract comprises 25-40% of total flavones, 15-30% of total phenolic acids, 10-20% of propolis anthracene acid compounds, ≤3% of moisture, ≤2% of ash, and the balance of other natural propolis components; and the sum of acacetin, galangin and pinocembrin in the total flavones accounts for 30-50% of the mass of the total flavones. The production process comprises freezing and crushing, complex enzymolysis, ultrasonic-assisted ethanol extraction, dewaxing, macroporous adsorption resin purification and drying. The application combines enzymolysis and ultrasonic to significantly improve the extraction rate and purity of active ingredients, and the obtained propolis extract has clear components, high active ingredient content, few impurities, and the process is green and efficient, and is suitable for industrial production.